Elizabeth Walsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elizabeth Walsh has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Nicolas M Orsi
Leeds Institute of Medical Research, Faculty of Medicine, University of Leeds, Leeds, United Kingdom
2 shared publications- Andre Geraldes
Panakeia Technologies
1 shared publication - Andrew M Hanby
Leeds Institute of Medical Research, Faculty of Medicine, University of Leeds, Leeds, United Kingdom
1 shared publication - Dildar Rathore
Histopathology Department, St James's University Hospital, Leeds, United Kingdom
1 shared publication - Michael Bradley Drummond
Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1 shared publication - Narender Kumar
Department of Medicine, University of Cambridge, Cambridge, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 16 June 2026
- Vol. 15, e76785
Deep-Learning Solution Providing Molecular Marker Subtyping of Breast Cancer Whole Slide Images: Protocol for a UK Clinical Service Evaluation Study.
As the histopathology workforce continues to struggle and service demand continues to increase, it has become prudent to consider viable avenues to try to alleviate diagnostic workload burden. One such avenue is computer-based technologies (CBTs). Breast cancer (BC) is the most common malignant neoplasm in the United Kingdom and requires additional testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status at the time of histological diagnosis. This makes BC diagnostics a promising candidate for the application of an efficient CBT. However, for clinical acceptance, these technologies must prove that they work within a real-life diagnostic environment. We present a study protocol for a prospective clinical service evaluation aimed to validate a UK Conformity Assessed-marked CBT's ability to provide ER, PR, and HER2 results for invasive BCs from scanned hematoxylin and eosin-stained whole slide images. This protocol has been designed to use and mimic a preexisting digital pathology workflow within a National Health Service tertiary referral cancer center without disrupting normal patient care. Eligible cases are identified prospectively through the laboratory information management system, and their whole slide images are extracted from the clinical digital workflow. After verification of national data opt-out status and the exclusion of appropriate cases (N=400 analyzable cases), these cases are analyzed on a dedicated computer in parallel to the existing clinical workflow by a UK Conformity Assessed-marked deep learning-based CBT in a separate environment, providing results for ER, PR, and HER2 status. These results are compared to the ER, PR, and HER2 status reported on the corresponding pathology report. To evaluate the CBT's performance, a range of accepted concordance measures will be applied, including specificity, sensitivity, false-positive rate, false-negative rate, positive predictive value, and negative predictive value. Moreover, time stamps representing the duration of image analysis will also be collected. This study started in April 2025. There are no results to present, as this paper focuses on study design, and results have yet to be generated. As of March 2026, overall, 366 potentially analyzable cases have been collected. The anticipated end date of the study is May 2026 (400-case target). Results will be presented in a separate publication. This design assesses a CBT within a clinical environment while effectively eliminating any unwanted effects on patient care. This type of service evaluation provides a useful step to establish confidence in a CBT before trialing its effect on patient care. It also offers the opportunity to support interventional randomized controlled trials, health economic evaluations, and usability studies. This protocol will hopefully prove useful to others who wish to conduct a similar service evaluation at their own institution. DERR1-10.2196/76785.
- 16 June 2026
- Vol. 15, e76785
Open AccessDeep-Learning Solution Providing Molecular Marker Subtyping of Breast Cancer Whole Slide Images: Protocol for a UK Clinical Service Evaluation Study.
As the histopathology workforce continues to struggle and service demand continues to increase, it has become prudent to consider viable avenues to try to alleviate diagnostic workload burden. One such avenue is computer-based technologies (CBTs). Breast cancer (BC) is the most common malignant neoplasm in the United Kingdom and requires additional testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status at the time of histological diagnosis. This makes BC diagnostics a promising candidate for the application of an efficient CBT. However, for clinical acceptance, these technologies must prove that they work within a real-life diagnostic environment. We present a study protocol for a prospective clinical service evaluation aimed to validate a UK Conformity Assessed-marked CBT's ability to provide ER, PR, and HER2 results for invasive BCs from scanned hematoxylin and eosin-stained whole slide images. This protocol has been designed to use and mimic a preexisting digital pathology workflow within a National Health Service tertiary referral cancer center without disrupting normal patient care. Eligible cases are identified prospectively through the laboratory information management system, and their whole slide images are extracted from the clinical digital workflow. After verification of national data opt-out status and the exclusion of appropriate cases (N=400 analyzable cases), these cases are analyzed on a dedicated computer in parallel to the existing clinical workflow by a UK Conformity Assessed-marked deep learning-based CBT in a separate environment, providing results for ER, PR, and HER2 status. These results are compared to the ER, PR, and HER2 status reported on the corresponding pathology report. To evaluate the CBT's performance, a range of accepted concordance measures will be applied, including specificity, sensitivity, false-positive rate, false-negative rate, positive predictive value, and negative predictive value. Moreover, time stamps representing the duration of image analysis will also be collected. This study started in April 2025. There are no results to present, as this paper focuses on study design, and results have yet to be generated. As of March 2026, overall, 366 potentially analyzable cases have been collected. The anticipated end date of the study is May 2026 (400-case target). Results will be presented in a separate publication. This design assesses a CBT within a clinical environment while effectively eliminating any unwanted effects on patient care. This type of service evaluation provides a useful step to establish confidence in a CBT before trialing its effect on patient care. It also offers the opportunity to support interventional randomized controlled trials, health economic evaluations, and usability studies. This protocol will hopefully prove useful to others who wish to conduct a similar service evaluation at their own institution. DERR1-10.2196/76785.
- Top Cited PapersOpen Access
- 21 December 2024
- Published by Springer Nature in Diagnostic Pathology
- Vol. 19 (1) , 1-10
The current troubled state of the global pathology workforce: a concise review
The histopathology workforce is a cornerstone of cancer diagnostics and is essential to the delivery of cancer services and patient care. The workforce has been subject to significant pressures over recent years, and this review considers them in the UK and internationally. These pressures include declining pathologist numbers, the increasing age of the workforce, and greater workload volume and complexity. Forecasts of the workforce’s future in numerous countries are also not favourable – although this is not universal. Some in the field suggest that the effects of these pressures are already coming to bear, such as the financial costs of the additional measures needed to maintain clinical services. There is also some evidence of a detrimental impact on service delivery, patient care and pathologists themselves. Various solutions have been considered, including increasing the number of training places, enhancing recruitment, shortening pathology training and establishing additional support roles within pathology departments. A few studies have examined the effect of some of these solutions. However, the broader extent of their implementation and impact, if any, remains to be determined. In this regard, it is critical that future endeavours should focus on gaining a better understanding of the benefits of implemented workforce solutions, as well as obtaining more detailed and updated pathology workforce numbers. With a concentrated effort in these areas, the future of the pathology workforce could become brighter in the face of the increased demands on its services.
- 21 December 2024
- Published by Springer Nature in Diagnostic Pathology
- Vol. 19 (1) , 1-10
Top Cited PapersOpen AccessThe current troubled state of the global pathology workforce: a concise review
The histopathology workforce is a cornerstone of cancer diagnostics and is essential to the delivery of cancer services and patient care. The workforce has been subject to significant pressures over recent years, and this review considers them in the UK and internationally. These pressures include declining pathologist numbers, the increasing age of the workforce, and greater workload volume and complexity. Forecasts of the workforce’s future in numerous countries are also not favourable – although this is not universal. Some in the field suggest that the effects of these pressures are already coming to bear, such as the financial costs of the additional measures needed to maintain clinical services. There is also some evidence of a detrimental impact on service delivery, patient care and pathologists themselves. Various solutions have been considered, including increasing the number of training places, enhancing recruitment, shortening pathology training and establishing additional support roles within pathology departments. A few studies have examined the effect of some of these solutions. However, the broader extent of their implementation and impact, if any, remains to be determined. In this regard, it is critical that future endeavours should focus on gaining a better understanding of the benefits of implemented workforce solutions, as well as obtaining more detailed and updated pathology workforce numbers. With a concentrated effort in these areas, the future of the pathology workforce could become brighter in the face of the increased demands on its services.